13F Holdings
中文EN

ISCO International Stem Cell CORP

Pharmaceutical Preparations · OTC · SEC CIK 1355790 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.4%
TTM net income YoY-141.5%
TTM EPS YoY-75.0%
Revenue 3-yr CAGR5.7%
Net income 3-yr CAGR—

Margins

Gross margin55.0%
Operating margin-4.7%
Net margin-6.1%
FCF margin3.5%
EBITDA margin-2.9%

Returns

ROE—
ROA-11.0%
ROIC (approx.)—
Asset turnover1.79x

Leverage & solvency

Liabilities / assets98.6%
Debt / equity—
Current ratio0.79x
Interest coverage-3.15x

Cash quality & payout

Operating cash flow / net income-0.63x
Accruals ratio-17.9%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$9.10M$9.09M$7.79M$8.18M$7.18M
Cost of revenue$4.03M$3.76M$3.18M$3.27M$2.94M
Gross profit$5.07M$5.32M$4.61M$4.91M$4.24M
R&D expense$684,000$657,000$511,000$492,000$695,000
SG&A expense$3.53M$3.52M$3.51M$3.36M$4.08M
Operating income-$267,000-$68,000-$663,000-$183,000-$1.92M
Interest expense$151,000$145,000$139,000$135,000$128,000
Pretax income-$418,000-$209,000-$131,000-$331,000—
Income tax$0$0———
Net income-$418,000-$209,000-$131,000-$331,000-$899,000
EBITDA-$48,000$138,000-$469,000$35,000-$1.66M
EPS (basic)-0.05-0.03-0.02-0.04-0.11
EPS (diluted)-0.05-0.03-0.02-0.04-0.11
Weighted avg. shares (diluted)8.00M8.00M8.00M8.00M7.83M
Balance sheet
Cash & equivalents$993,000$1.23M$1.59M$742,000$171,000
Receivables$723,000$1.06M$574,000$747,000$844,000
Inventory$1.51M$1.15M$1.26M$1.38M$1.18M
Current assets$3.41M$3.56M$3.52M$2.96M$2.33M
PP&E, net$160,000$257,000$215,000$248,000$384,000
Intangibles$644,000$721,000$800,000$878,000$949,000
Total assets$4.82M$5.17M$5.39M$5.13M$4.95M
Current liabilities$4.58M$4.69M$4.83M$4.63M$4.28M
Total liabilities$4.58M$4.80M$5.28M$5.36M$5.23M
Shareholders' equity-$4.06M-$3.93M-$4.19M-$4.52M-$4.59M
Shares outstanding8.00M8.00M8.00M8.00M8.00M
Cash flow statement
Operating cash flow$8,000$13,000$929,000$332,000-$1.30M
Capital expenditure$43,000$166,000$80,000$1,000$23,000
Free cash flow-$35,000-$153,000$849,000$331,000-$1.32M
Investing cash flow-$45,000-$171,000-$83,000-$11,000-$45,000
Financing cash flow-$200,000-$200,000—$250,000$824,000
Depreciation & amortization$219,000$206,000$194,000$218,000$262,000
Stock-based compensation$288,000$466,000$464,000$399,000$644,000

Free plan shows the latest 5 periods; Pro shows all 20 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.